IOVA241122C21000
- 0.00
- 0.000.00%
Iovance Biotherapeutics Newsroom
Iovance Biotherapeutics Optimizes Headquarters for Cost Efficiency
High Quality 'SMID-cap' Stocks With Cyclical Exposure – MS
JMP Securities Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $23
Iovance Biotherapeutics: Promising Growth and Expansion in Cancer Treatment Fuels Buy Rating
A Quick Look at Today's Ratings for Iovance Biotherapeutics(IOVA.US), With a Forecast Between $21 to $32
Express News | Iovance Biotherapeutics Inc : Stifel Cuts Target Price to $21 From $23
Iovance Biotherapeutics Inc (IOVA) Q3 2024 Earnings Call Highlights: Surpassing Revenue ...
Iovance Biotherapeutics, Inc. (IOVA) Q3 2024 Earnings Call Transcript Summary
TD Cowen Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating
Optimistic Outlook for Iovance Biotherapeutics With Strong Q3 Performance and Growth Potential
Iovance Falls 12% Despite Q3 Beats; Reaffirms 2024 Revenue Guidance
Iovance Biotherapeutics | 10-Q: Q3 2024 Earnings Report
Iovance Biotherapeutics Affirms FY2024 Product Sales Guidance From $160.00M-165.00M to $160.00M-165.00M
Iovance Biotherapeutics | 8-K: Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024
Earnings Flash (IOVA) IOVANCE BIOTHERAPEUTICS Posts Q3 Revenue $58.6M
Iovance Biotherapeutics GAAP EPS of -$0.28 Beats by $0.02, Revenue of $58.6M Beats by $4.78M
Express News | Iovance Biotherapeutics Q3 Net Income USD -83.541 Million
Press Release: Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024
Iovance Biotherapeutics 3Q Loss/Shr 28c >IOVA
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024